Patents by Agent Danica Hostettler

Patent number: 8318184
Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.
Type: Grant
Filed: December 15, 2010
Issued: November 27, 2012
Assignee: Eli Lilly and Company
Inventors: James Allen Monn, Lourdes Prieto, Lorena Taboada Martinez, Carlos Montero Salgado, Bruce William Shaw
Patent number: 8314108
Abstract: The present invention provides an aminopyrazole compound, more particularly, or a pharmaceutically acceptable salt thereof or a solvate of the salt, that inhibits Chk1 and is useful in the treatment of cancer.
Type: Grant
Filed: December 10, 2009
Issued: November 20, 2012
Assignee: Eli Lilly and Company
Inventors: Francine S. Farouz, Ryan Coatsworth Holcomb, Ramesh Kasar, Steven Scott Myers
Patent number: 8273742
Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
Type: Grant
Filed: June 15, 2010
Issued: September 25, 2012
Assignee: Eli Lilly and Company
Inventors: Philip Arthur Hipskind, Bharvin Kumar Patel, Takako Wilson (nee Takakuwa)
Patent number: 8222284
Abstract: The present invention provides formulation parameters and manufacturing conditions for stable pharmaceutical compositions comprising N-{4-(2,2-dimethyl-propionyl)-(5R)-5-[(2-ethylamino-ethanesulfonylamino)-methyl]-5-phenyl-4,5-dihydro-[1,3,4]thiadiazol-2-yl}-2,2-dimethyl-propionamide that minimize undesirable chiral conversion to the less active S enantiomeric form.
Type: Grant
Filed: July 7, 2008
Issued: July 17, 2012
Assignees: Eli Lilly and Company, Kyowa Hakko Kirin Co., Ltd.
Inventors: Hiroko Kusano, Dinesh Shyamdeo Mishra, Yoshikazu Tashiro, Yosuke Watanabe, Hong Zhuang
Patent number: 8153683
Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
Type: Grant
Filed: May 4, 2011
Issued: April 10, 2012
Assignee: Eli Lilly and Company
Inventors: Eric David Moher, James Allen Monn
Patent number: 8093244
Abstract: Substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division, also are disclosed.
Type: Grant
Filed: March 29, 2006
Issued: January 10, 2012
Assignee: ICOS Corporation
Inventors: Frank Diaz, Francine S. Farouz, Ryan Coatsworth Holcomb, Edward A. Kesicki, Kimba Lee Fischer, Adam Wade Cook
Patent number: 7981892
Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
Type: Grant
Filed: April 1, 2009
Issued: July 19, 2011
Assignee: Eli Lilly and Company
Inventors: Philip Arthur Hipskind, Takako Wilson (nee Takakuwa)
Patent number: 7964632
Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
Type: Grant
Filed: January 15, 2010
Issued: June 21, 2011
Assignee: Eli Lilly and Company
Inventors: Eric David Moher, James Allen Monn, Concepcion Pedregal-Tercero, Ivan Collado CaƱo, Jaime Gonzalo Blanco-Urgoiti
Patent number: 7855211
Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.
Type: Grant
Filed: December 15, 2009
Issued: December 21, 2010
Assignee: Eli Lilly and Company
Inventors: David A Coates, Lawrence Mark Gelbert, John M. Knobeloch, Alfonso De Dios Magana, Ana De Prado Gonzalez, Miriam Filadelfa Del Prado Catalina, Maria Cristina Garcia Paredes, Eva Maria Martin De La Nava, Maria Dolores Martin Ortega Finger, Jose Antonio Martinez Perez, Ana Isabel Mateo Herranz, Carlos Perez Martinez, Concepcion Sanchez Martinez
Patent number: 7671082
Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
Type: Grant
Filed: March 31, 2008
Issued: March 2, 2010
Assignee: Eli Lilly and Company
Inventors: Eric David Moher, James Allen Monn
Patent number: 7511056
Abstract: The present invention is directed to inhibitors of TGF-? of Formula I:
Type: Grant
Filed: November 2, 2005
Issued: March 31, 2009
Assignee: Eli Lilly and Company
Inventors: Clive Gideon Diefenbacher, Thomas Albert Engler, Hong-Yu Li, Sushant Malhotra, Jason Scott Sawyer, Yan Wang
Patent number: 7511065
Abstract: The present invention provides a compound of the formula: (Formula I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.
Type: Grant
Filed: November 12, 2003
Issued: March 31, 2009
Assignee: Eli Lilly and Company
Inventors: Theodore Goodson, Jr., Mary Margaret Mader, John Eldon Toth, Arindam Chatterjee, Jason Scott Sawyer
Patent number: 7456221
Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
Type: Grant
Filed: July 5, 2007
Issued: November 25, 2008
Assignee: Eli Lilly and Company
Inventors: David Scott Coffey, James Allen Monn, Concepcion Pedregal-Tercero, Steven Wayne Pedersen
Patent number: 7449477
Abstract: The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
Type: Grant
Filed: November 22, 2004
Issued: November 11, 2008
Assignee: Eli Lilly and Company
Inventors: David Anthony Barda, Kenneth James Henry, Jr., Jianping Huang, Sajan Joseph, Ho-Shen Lin, Michael Enrico Richett
Patent number: 7414063
Abstract: The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
Type: Grant
Filed: March 25, 2004
Issued: August 19, 2008
Assignee: Eli Lilly and Company
Inventors: Rima Salim Al-Awar, David Anthony Barda, Albert Gerard Dee, Kenneth James Henry, Jr., Sajan Joseph, Ho-Shen Lin, Jose Eduardo Lopez, Michael Enrico Richett, Carmen Somoza
Patent number: 7405299
Abstract: The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.
Type: Grant
Filed: November 24, 2003
Issued: July 29, 2008
Assignee: Eli Lilly and Company
Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Todd Vincent Decollo, Alexander Glenn Godfrey, Charles Raymond Heap, Chi-Hsin Richard King, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Yan Wang, Clive Gideon Diefenbacher, Thomas Albert Engler, Sushant Malhotra, Sreenivasa Reedy Mundla
Patent number: 7371872
Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
Type: Grant
Filed: June 6, 2003
Issued: May 13, 2008
Assignee: Eli Lilly and Company
Inventors: Eric David Moher, James Allen Monn
Patent number: 7368445
Abstract: The disclosed invention is directed to compounds of the formula: Formula (I) and methods of using these compounds.
Type: Grant
Filed: February 16, 2005
Issued: May 6, 2008
Assignee: Eli Lilly and Company
Inventors: Hong-Yu Li, William Thomas McMillen, Yan Wang
Patent number: 7265246
Abstract: The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor
Type: Grant
Filed: June 23, 2004
Issued: September 4, 2007
Assignee: Eli Lilly and Company
Inventors: Jennifer Rebecca Allen, Stephen Andrew Hitchcock, Bin Liu, William Wilson Turner
Patent number: 7256217
Abstract: This invention relates to synthetic excitatory amino acid prodrugs according to formula (I) and processes for their preparation.
Type: Grant
Filed: December 14, 2001
Issued: August 14, 2007
Assignee: Eli Lilly and Company
Inventors: David Scott Coffey, James Allen Monn, Concepcion Pedregal-Tercero, Steven Wayne Pedersen
1 2 next